Covid-19 – Day 701: Omicron Severity and Transmission
(E) The LKS Faculty of Medicine at the University of Hong Kong found in a new research study why Omicron is less dangerous than Delta but more viral than Delta. […]
Covid-19 – Day 685: What do we Know about Omicron?
(E) What do we know about the SARS-Cov-2 variant named Omicron? From what I understood, not much, except that its spike protein has many more mutations than the Delta variant […]
Covid-19 – Day 627: Merck and Ridgeback Biotherapeutics Covid-19 Oral Antiviral Treatment
(E) The beautiful city of Manaus, full of history about the Amazonas, reached natural herd immunity in the Fall of 2020 when around 75% to 80% of its population had […]
Covid-19 – Day 613: Covid Patients Transported from Tahiti to Paris
(E) Eight French Polynesian patients in intensive care from Covid-19 were transported on Friday, September 17th on a plane from Tahiti to Paris in a 22 hours flight. The cost […]
Covid-19 – Day 566: State of Knowledge about the Delta Variant
(E) A few recent articles that summarize the present state of knowledge about the Delta variant from the revue Nature: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization How […]
Covid-19 – Day 503: A Summary of Machine Learning Contributions to Stop the Pandemic
(T) An excellent article from Maxime Nauwynck on “how has AI contributed to dealing with the COVID-19 pandemic?” published in Stanford Gradient’s blog. The article looks at the contribution in […]
COVID-19 – Day 491: The Adjuvanted Recombinant Protein Vaccine from Sanofi-GSK
(E) Sanofi, the largest vaccine manufacturer in the world, and its partner GSK just announced the result of their vaccine that is based on an adjuvanted recombinant protein for their […]
COVID-19 – Day 475: Countries with or without the SARS-Cov-2
(E) There are countries such as New Zealand and Taiwan, where political and health care officials do not tolerate any spread of the SARS-Cov-2 (note that the political leaders in […]
COVID-19 – Day 466: Understanding the Non-Modified mRNA Vaccine from CureVac
(E) Another remarkable blog article, “the CureVac Vaccine, and a brief tour through some of the wonders of nature“, from (software engineer) blogger Bert Hubert who also wrote last year […]
COVID-19 – Day 464: The Supply Chain of the mRNA Vaccines
(E) A remarkable blog article, “exploring the Supply Chain of the Pfizer/BioNTech and Moderna COVID-19 vaccines“, from another (software engineer) blogger Jonas Neubert on discovering and understanding the supply chain […]
COVID-19 – Day 457: Got my 2nd Dose of Covid-19 Vaccine Today
(E) I feel very privileged to not only have received my second Covid-19 vaccine dose today but also that my two doses were an mRNA vaccine, the one from Pfizer-BioNtech. […]
Covid-19 – Day 426: Understanding the Long Term Effects of Covid-19 on the Body
(E) A very interesting article on Professor Ron Davis, from the Stanford Genome Technology Center, trying to save his son from the long-term effects of myalgic encephalomyelitis — a disease […]
Covid-19 – Day 421: Mapping T Cell Receptors to Covid-19 Antigens
(T) A biotech company Adaptive Biotechnologies has developed a new test, called T-Detect Covid, that looks at signals of past Covid infections in the body T cells immune system. The […]
Covid-19 – Day 381: Meet Dr. Katalina Karikó and Dr. Drew Weissman – the two Beautiful Minds behind the COVID-19 mRNA Vaccines
(E) We have now known for over a year the two companies that delivered the first two Covid-19 vaccines – BioNtech and Moderna, based on mRNA. What we are now […]
Predicting SARS-CoV-2, HIV, and Influenza Viral Mutations with Language Models
(T) In this third blog post about the applications of deep learning techniques to structural biology research, I will summarize a recent research study on virus mutation.The recent Covid-19 pandemic […]
Covid-19 – Day 369: Moderna’s Vaccine Boost Against the Variant from South Africa (B1.351)
(E) Moderna released today new data about the protection of its vaccine against the new SARS-Cov-2 variants: “Moderna COVID-19 Vaccine Variants Update“. Long story short, the Moderna vaccine provides the […]
Covid-19 – Day 369: Finally Moderna’s Finished Phase 3
(E) Today, Moderna announced the results of its phase 3 study, and gave some additional details about its vaccine. Moderna vaccine is slightly more efficient than the one from BioNTech, […]
Covid-19 – Day 369: The Second Wave is Here!
(E) The second wave is here. Infections have been rising to the roof: Europe, the U.S., South America, and Russia. The U.S have now over 150,000 new daily cases, and […]
Covid-19 – Day 361: BioNTech and Pfizer Vaccine for the SARS-CoV-2
(E) Today is a good day! Pharmaceutical giant partner Pfizer announced today that the vaccine developed with its partner BioNTech, a bio-tech company located in Mainz in Germany, against the […]
Covid-19 – Day 359: Slovakia Attempting to Test Entire Adult Population for Covid
(E) Taiwan and New Zealand have a huge advantage over other countries fighting the propagation of SARS-CoV-2: they are islands. Closing and reopening offices, schools, restaurants, gyms do not work. […]
COVID-19 – Day 206: Looking back at the Mistakes that Caused Human Lives
(E) Looking back at the mistakes that caused human lives, Professor Philippe Parola, directeur de service de soins et d’unité de recherche à L’Institut Hospitalo-Universitaire (IHU) de Marseilles, looked back […]
Covid-19 – Day 158: A SARS-CoV-2 Protein Interaction Map to Repurpose Antiviral Drugs
(E) Excellent research from UCSF, Institut Pasteur, Gladstone Institutes, and Icahn School of Medicine at Mount Sinai to find the right antiviral drugs for Covid-19: “A SARS-CoV-2 protein interaction map […]
Covid-19 – Day 157: Yale School of Medicine Updated Treatment for Hospitalized Patients with Non–Severe COVID-19
(E) Yale School of Medicine has updated its initial treatment algorithm for hospitalized patients with non–severe COVID-19 which uses hydroxychloroquine and tocilizumab: Yale Releases COVID-19 Treatment Algorithm Covid-19 adult treatment […]
A Silicon Valley Insider 